Out-of-specification (OOS) results were found in reference samples for atomoxetine content, below the lower specification limit; for one batch also non-compliance in capsule mass uniformity; the impact on safety was assessed as low. Potential effects: reduced treatment effectiveness, possible worsening of symptoms, risk of complications due to poor disease control.
Download the app and stay informed
Get instant notifications about recalled products and protect your family.
Important Information
Do not use the product from the listed batches. Patients should check the batch number on the pack, return any affected product to the pharmacy, and consult a doctor or pharmacist about the need for a...
The Chief Pharmaceutical Inspector withdrew the specified batches of Konaten (Atomoxetine) from the market nationwide, prohibited their placing on the market, and granted the decision immediate enforc...
If you feel unwell after consuming this product, contact your doctor or call the poison control center.
FAQ
Related